Sign Out
CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY: Cardiomyopathy: Vivitra can result in sub-clinical and clinical cardiac failure manifesting as Congestive heart failure (CHF) and decreased Left ventricular ejection fraction (LVEF) with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Vivitra for cardiomyopathy.
Infusion reactions, Pulmonary toxicity: Discontinue Vivitra for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Embryo-Fetal Toxicity: Exposure to Vivitra during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death.
